BRIBF (Brii Biosciences) Moat Score: 4/10 (As of Jun. 29, 2026)


BRIBF Brii Biosciences Ltd BRIBF
34 GF Score
Price $0.15
! 1 Warning Sign
View Full Analysis

What is Brii Biosciences Moat Score?

Brii Biosciences BRIBF 34 Moat Score is 4 as of Jun. 29, 2026. GuruFocus rates BRIBF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,401 Biotechnology companies, Brii Biosciences ranks better than 88.79% on this metric.

Brii Biosciences has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Brii Biosciences has Narrow Moat: Brii Biosciences has some valuable intellectual property and patents in the biotech sector. However, it lacks strong brand strength and customer loyalty. The company has modest regulatory barriers but limited pricing power and distribution network.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Brii Biosciences might have Narrow Moat - Discernible but modest moat.

Brii Biosciences  (OTCPK:BRIBF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Brii Biosciences Moat Score Related Terms

BRIBF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Brii Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brii Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Moat Score falls into.


BRIBF
34GF Score
Brii Biosciences Ltd BRIBF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Brii Biosciences (BRIBF) has a Moat Score of 4 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Brii Biosciences ranks #157 out of 1401 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Brii Biosciences' Moat Score too high?
Brii Biosciences' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Brii Biosciences' value of 4 is 100% above this industry median. Based on the distribution chart, Brii Biosciences ranks #157 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Brii Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #157 out of 1401 companies for Moat Score. This places Brii Biosciences in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Brii Biosciences' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brii Biosciences's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brii Biosciences's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (BRIBF) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Brii Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Brii Biosciences (BRIBF), the current Moat Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brii Biosciences Business Description

Other Exchanges 02137:Hong Kong7SS:Germany
Address No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
34GF Score

Get the complete analysis for BRIBF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price